Why Compounding Pharmacies Are Fighting Lilly's Retatrutide Biologic Bid
TL;DR: A compounders' trade group calls Lilly's retatrutide biologic bid a "money grab" ahead of the 24 Sept Seventh Circuit hearing.
What's New: A Compounding Trade Group Weighs In
Until now, our coverage of Eli Lilly's fight with the FDA over how retatrutide should be classified — as a conventional drug reviewable under a New Drug Application (NDA), or as a biological product reviewable under a Biologics License Application (BLA) — has tracked the two named parties: Lilly and the agency.[1] A 10 September 2026 analysis in Reason magazine, and subsequent trade-press commentary on the case, adds a third voice that has been reported ahead of the 24 September Seventh Circuit hearing: the Outsourcing Facilities Association (OFA), a US trade group representing large-scale compounding pharmacies, which has been characterised as backing the FDA's position and dismissing Lilly's appeal as a "money grab."[2]
That framing matters because it reveals a stakeholder whose interest in the case has nothing to do with the underlying amino-acid-counting dispute, and everything to do with what a biologic designation would do to the compounding pathway for retatrutide once it is eventually approved.
Who Is the Outsourcing Facilities Association, and Why Does It Care?
The OFA represents 503B outsourcing facilities — large, FDA-registered compounding pharmacies that prepare medicines in bulk under current good manufacturing practice rules, as distinct from the smaller 503A pharmacies that compound to an individual patient's prescription. The association is a regular amicus participant in FDA classification and compounding-exemption litigation, including cases before the Fifth Circuit and the US Supreme Court concerning which products fall inside the statutory compounding carve-outs.[3]
Why the classification outcome affects compounders directly
Sections 503A and 503B of the Food, Drug and Cosmetic Act let registered pharmacies compound certain drug products, generally under conditions such as an FDA-recognised shortage. Biological products regulated under the Public Health Service Act do not carry the same compounding exemption. A biologic designation for retatrutide would close that pathway for good; an NDA designation leaves it open in principle, subject to separate FDA rules.
Why the OFA calls it a "money grab"
Trade-press commentary on the OFA's position frames Lilly's push for biologic status as pursuing a "windfall at the expense of patients": longer exclusivity, slower biosimilar competition, and a designation that happens to also foreclose future compounded versions, rather than a dispute genuinely about retatrutide's molecular structure.
We should be precise about what is, and is not, established here. The OFA's opposition is reported by trade press as industry commentary and advocacy, not as a party brief we have independently reviewed on the Seventh Circuit's docket, and neither Lilly nor the FDA has responded on the record to the "money grab" characterisation as far as our sources show. We are reporting what has been reported, not adjudicating the underlying dispute.
The Exclusivity Math Behind the Fight
The numbers explain why a two-letter statutory label is worth fighting over. A BLA carries roughly 12 years of exclusivity against biosimilar competition under the Biologics Price Competition and Innovation Act. An NDA typically carries about five years of new-chemical-entity exclusivity under the Hatch-Waxman framework — a gap of roughly seven years on the same molecule, which we set out in more detail in our original report on the classification fight.[4]
| Factor | If classified as a biologic (BLA) | If classified as a drug (NDA) |
|---|---|---|
| Post-approval exclusivity | ~12 years | ~5 years |
| Compounding exemption | Not available | Available in principle, subject to FDA shortage rules |
| Follow-on competition route | Biosimilar pathway (351(k)) | Generic ANDA pathway |
| Who this benefits | Lilly, per the OFA's framing | Compounding pharmacies, per the OFA's framing |
Neither side disputes the exclusivity numbers themselves; what is contested is whether that consequence should carry any legal weight, or whether the sole question is the narrow scientific one the district court remanded: whether retatrutide is "analogous to a protein." The OFA's amicus-style commentary is an argument that the practical stakes are relevant to how the court should read the statute — a position the FDA has not needed to make itself, since it aligns with the agency's own drug classification.
Does This Affect the UK Research-Reagent Market?
No. This is a dispute among US parties — a licensed pharmaceutical company, its federal regulator, and a US compounding-pharmacy trade association — over which American regulatory pathway applies to an investigational drug and what that pathway means for US 503A/503B compounding. It has no bearing on the UK regulatory position for research reagents, which sits under the Human Medicines Regulations 2012 and MHRA guidance; see our guide on whether research peptides are legal in the UK. Retatrutide remains unlicensed for human use everywhere, regardless of how the classification fight, the compounding-exemption question, or the 24 September hearing resolve.
What this does not do. This dispute does not change retatrutide's regulatory status today, does not affect any completed Phase 3 trial data, and does not create or remove any legal route to human use in the UK or anywhere else. Retatrutide remains an investigational compound, available to Velox Peptides customers only as an in vitro research reagent.
Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Velox Peptides. Retatrutide's FDA Biologic Classification Fight. See our full background report on the underlying litigation, filed 3 September 2024 and on appeal since 13 February 2026.
- Reason. Can a New Weight Loss Treatment Escape the Legal and Regulatory Thicket? 10 September 2026. reason.com
- Outsourcing Facilities Association. Amicus filings in FDA compounding-exemption litigation, including proceedings before the Fifth Circuit and the US Supreme Court. supremecourt.gov
- Goodwin Law Insights. District Court Sets Aside FDA's Interpretation of "Analogous" to a Protein for Purposes of the "Biological Product" Category. October 2025. goodwinlaw.com
- Velox Peptides. What to Expect at the Retatrutide Seventh Circuit Hearing on 24 September. See our hearing preview for the arguments each named party is expected to make.
Frequently Asked Questions
Who is the Outsourcing Facilities Association?
The Outsourcing Facilities Association (OFA) is a US trade association representing 503B outsourcing facilities — the large-scale compounding pharmacies that prepare medicines under FDA-registered facility rules, distinct from the smaller 503A pharmacies that compound to individual prescriptions. The OFA regularly files amicus briefs in FDA classification and compounding-exemption litigation.
Why does a drug-vs-biologic classification affect compounding?
Sections 503A and 503B of the Food, Drug and Cosmetic Act, which let registered pharmacies compound versions of certain drugs, apply to conventional drug products. Biological products regulated under the Public Health Service Act generally fall outside that compounding exemption. If retatrutide is classified as a biologic, that legal pathway for future compounded versions closes; if it stays a drug, it remains open in principle, subject to separate FDA shortage and exemption rules.
What did the trade press report about the OFA's position?
A 10 September 2026 Reason magazine analysis, along with other trade-press commentary on the case, reported that the OFA has argued Lilly's push for biologic status functions as a bid for a longer exclusivity window rather than a scientific classification dispute, framing it as pursuing a "windfall at the expense of patients" — trade-press shorthand quoted as calling the manoeuvre a "money grab."
Does this dispute affect UK research-reagent supply of retatrutide?
No. This is a US trade-association dispute over which American regulatory pathway a licensed pharmaceutical company must use, and how that pathway affects US compounding pharmacies. It has no bearing on the UK regulatory position for research reagents under the Human Medicines Regulations 2012. Velox Peptides supplies retatrutide as an HPLC-verified in vitro research reagent only, a status unrelated to this litigation. Order for research →
When will the Seventh Circuit rule on the underlying appeal?
Oral arguments are set for 24 September 2026. Appellate panels do not rule from the bench — a written opinion typically follows weeks to several months after argument, so a decision is not expected on the hearing date itself.